13F 20+/2-×0.0 · short↓0.32
Current snapshotPublic companyResearch currentFresh
BillionToOne Corp
Read · Healthspan Infrastructure
SignalPOOLReviewed 25 Oct 2026
Read exposure in Healthspan Infrastructure.
POOL tier healthspan — no action. Q2 earnings Aug 5 could provide catalyst data. NEEDS_MORE_DATA thesis status.
Catalysts
Q2 2026 earnings Aug 5 (UNITY Confirm launch traction May 1, guidance raise to $450-465M); tumor-naive MRD test commercial launch late 2026 + clinical data readout; Medicare coverage decisions Q3/Q4 2026 for Northstar Response; Northstar Select head-to-head superiority data vs commercial CGP panels
Invalidation
1) Q3 2026 clean qoq growth <5% AND operating margin stays <8% — confirms the 'reversing operating leverage + mix shift' bear case rather than a temporary true-up blip. 2) MolDX Medicare coverage for Northstar Response slips past end-2026 or is denied — the oncology optionality (main re-rate driver) deflates. 3) AR continues to outpace revenue (already +80% H1 vs ~+44% revenue) with the >$10M national in-network payer claims unprocessed past Q3 — reimbursement-collection risk materializes and the true-up/ASP model loses credibility. 4) NGS cost compression (Natera/Guardant cutting panel COGS or launching cost-competitive targeted assays) erodes the QCT COGS asymmetry underpinning the thesis.
Latest change
· Target moved from $122.82 to $122.73.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
Neutral-Bearish - Insider T. Lynch sold $3.9M shares Sep 17 at $110.33 (-98% disposed). [X/web search Sep 2026]
Lower-confidence snapshotTarget price: $126.37
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Moat Durability
- Durable IP
- Toll Road Tier
- Weak proxy
Timestamped research update
Deep research update
1,450 words · Updated 13 Sept 2026 · 4 sources
| Metric | Value | Source |
|---|---|---|
| Q2 2026 revenue | $109.45M (+64.4% YoY) | 10-Q (08-05-2026) |
| Prenatal / Oncology split | ~$94.2M (+55%) / $13.7M (+176%) | Q2 call |
| Q2 gross margin | 70.4% (vs 65.3% YoY) | 10-Q |
| Q2 operating income | $5.50M (5.0% margin; Q1 was $17.83M / 16.5%) | 10-Q + XBRL |
| Q2 net income | $8.05M ($0.15 diluted EPS) | 10-Q |
| FY2025 revenue | $305.1M (FY24 $152.6M, FY23 $71.7M) | 10-K + XBRL |
| FY2026 guidance | $450–465M (+48–52%) | Q2 call |
| Cash & equivalents | $548.6M (06-30-2026) | 10-Q |
| Long-term debt | $91.0M (Oberland Capital 2024 Notes, fair-value opt) | 10-Q |
| Accounts receivable | $74.9M (+80% vs $41.6M at YE25) | 10-Q |
| Operating / FCF | $9.1M OCF / $5.1M FCF (Q2) | Q2 call |
Balance sheet is clean for a growth diagnostic: $548.6M cash vs $91.0M debt = ~$458M net cash against a ~$4.6B market cap (at ~$98/sh × ~47M shares). GAAP-profitable two straight quarters (Q1 $17.97M, Q2 $8.05M net income).
- monetization model: Fee-for-service clinical lab testing (per-test reimbursement/CPT codes); no subscription/hardware/license model disclosed. (BLLN 10-K, Business & Revenue notes, sec.gov ; accession UNKNOWN)
- revenue mix: One reportable segment; prenatal UNITY tests primary, oncology Northstar emerging; exact % split UNKNOWN. (BLLN 10-K, Segment/Revenue notes; accession UNKNOWN)
- who pays: Third-party payers (commercial/Medicaid), patients (self-pay/coinsurance), health systems/providers as ordering/billing parties. (BLLN 10-K, Business; accession UNKNOWN)
- margin_value_capture: Gross margin on lab services; value accrues in proprietary assay + payer coverage; exact GM/OM UNKNOWN. (BLLN 10-K, MD&A; accession UNKNOWN)
- customer classes: Health Systems & Providers, Payers & Insurers, Consumers (D2C Healthspan). (BLLN 10-K, Business; accession UNKNOWN)
1. The "deceleration" is substantially a true-up accounting artifact.
H1 2026 revenue included $12.0M of prior-period performance-obligation revenue (payor re-agreement reprocessing of 2025 claims): $9.2M in Q1, $2.8M in Q2 (10-Q Note 2). Stripping the true-ups:
- Q1 clean = $108.39M − $9.2M = $99.2M
- Q2 clean = $109.45M − $2.8M = $106.6M
- Clean qoq = +7.5%, vs the headline +1.0% that triggered the ~30% after-hours sell-off. The market over-read a sequential stall that was mostly an accounting normalization.
2. Growth decomposition confirms volume + price both rising.
Q2 revenue +64% YoY = +35% test volume × +21% ASP (earnings call). 1.35 × 1.21 = 1.63 ≈ 1.64. This is real unit-share gain, not just price.
3. Cost-of-the-moat vs the moat it defends.
R&D = $17.3M/qtr = 15.8% of revenue (up from 17.7% a year ago) defends a ~70% GM franchise. SG&A = $54.3M/qtr = 49.6% of revenue, inflated by ~70 sales reps added in H1 2026 ahead of the MRD launch. The company is front-loading the commercial cost to defend/enlarge the oncology franchise before Medicare coverage unlocks.
4. Oncology mix-shift drag on blended margin.
Oncology revenue $13.7M/qtr (+176% YoY, ~$55M annualized run-rate, 12.5% of revenue) carries higher cost-per-test than prenatal. Blended GM fell 73.0% (Q1) → 70.4% (Q2) and op margin 16.5% → 5.0% as oncology mix rose and SG&A/R&D ramped. The structural question: does oncology GM approach prenatal GM once Northstar Response secures MolDX coverage and volume scales?
BillionToOne's QCT (Quantitative Counting Technology) measures copy-number variants and DNA methylation at the single-molecule level using quantitative PCR-style molecular counting instead of next-generation sequencing (NGS). The binding constraint is cost-per-test: NGS-based NIPT/liquid-biopsy competitors carry sequencer amortization + reagent + bioinformatics COGS of roughly $300–500/test, while QCT's counting chemistry runs a fraction of that, letting BLLN price 30–50% below Natera/Guardant and still hold ~70% gross margin. The economic limit governing the moat is the COGS asymmetry between qPCR-based counting and NGS — and, conversely, QCT's own multiplexing ceiling (it cannot broadly sequence; it counts a targeted set of loci), which is why the moat is strongest in targeted panels (NIPT/carrier screening, methylation MRD) and weaker in broad whole-genome oncology.
- QCT molecular-counting platform — proprietary single-molecule counting that quantifies CNVs and methylation without NGS; the company describes itself as "a precision diagnostics company that quantifies biology to create molecular diagnostics… detect and measure DNA molecules at the single-count level" (10-Q Note 1, filed 08-05-2026).
- UNITY — combined carrier screening + NIPT + fetal antigen (RhD) in a single blood draw; UNITY Confirm is the "first and only non-invasive confirmation assay for high-risk pregnancies" using intact fetal cells (Q2 2026 earnings call), ordered on >50% of eligible patients.
- Northstar (oncology) — methylation-based liquid biopsy: Northstar Response (tumor-naive MRD / treatment response) and Northstar Select (therapy selection). On track for MolDX Medicare coverage of Northstar Response by end-2026.
- Johnson & Johnson partnerships — Jan 2023 clinical-trial assay + March 2026 restated ~3-year extension; July 2025 companion-diagnostic (CDx) development deal for a J&J drug candidate (AZALEA Phase 3 referenced in 10-Q risk factors). These are revenue-bearing validation of the assay's regulatory/clinical credibility.
- product_service: UNITY prenatal cfDNA tests and Northstar oncology liquid biopsy. (BLLN 10-K, Business; accession UNKNOWN)
- technical function: QCT single-molecule counting of cfDNA to detect fetal aneuploidies, microdeletions, fetal antigens, and rare tumor variants. (BLLN 10-K, Business; accession UNKNOWN)
- why it is hard: Proprietary QCT chemistry, low fetal fraction sensitivity, clinical validation, payer coverage, lab automation. (BLLN 10-K, Business/Risk Factors; accession UNKNOWN)
- substitutes: Other NIPT (Natera, Labcorp, Quest), amniocentesis/ultrasound; tissue biopsy or other liquid biopsy for oncology. (BLLN 10-K, Competition/Risk Factors; accession UNKNOWN)
- pricing power: MED — reimbursement-based; differentiated tests but payer contracts constrain price. (BLLN 10-K, Business/Risk Factors; accession UNKNOWN)
- Prenatal/NIPT: Natera (Panorama), Labcorp (MaterniT), Myriad. BLLN's UNITY is differentiated by combining carrier screening + NIPT + fetal antigen in one draw at a lower price point enabled by QCT COGS.
- Oncology MRD: Natera (Signatera, tumor-informed — market leader), Guardant (Reveal, tumor-naive), Exact Sciences, Foundation Medicine. BLLN's Northstar Response is methylation-based (tumor-naive, no tissue needed), competing head-to-head with Reveal on the tumor-naive convenience axis. Northstar Select claims head-to-head superiority data vs commercial CGP panels (stub).
- Hyperscaler-style risk: the NGS incumbents are far larger (Natera, Guardant, Exact), with bigger sales forces and established MolDX codes — BLLN is the cost-advantage challenger, not the incumbent. The J&J relationship is a partial counterweight (pharma validation).
- Q3 2026 clean qoq growth <5% AND op margin stays <8% → the "reversing operating leverage + mix shift" bear case is confirmed, not a temporary true-up blip.
- MolDX Medicare coverage for Northstar Response slips past end-2026 or is denied → the oncology optionality (the main re-rate driver) deflates.
- AR continues to outpace revenue (already +80% H1 vs ~+44% revenue growth): if the >$10M of national in-network payer claims (coding implementation) stay unprocessed past Q3, reimbursement-collection risk materializes and the true-up/ASP model loses credibility.
- NGS cost compression (Natera/Guardant cutting panel COGS or launching cost-competitive targeted assays) erodes the QCT COGS asymmetry that underpins the whole thesis.
- 2026-08-05 — Q2 2026 results: revenue +64%, GAAP net income $8.1M, guidance reiterated $450–465M. Stock fell ~30% after-hours on the true-up-driven sequential decel + margin compression.
- MolDX Medicare coverage for Northstar Response — expected end-2026 (management: "one of our most meaningful catalysts").
- Tumor-naive MRD (Northstar Select) commercial launch — late 2026.
- UNITY Confirm — first/only non-invasive high-risk-pregnancy confirmation assay, >50% adoption on eligible patients.
- J&J AZALEA Phase 3 trial progression (CDx revenue path).
- technical_scarcity: 7/10 — QCT is genuinely proprietary single-molecule counting (distinct from NGS) with a durable COGS asymmetry and pharma (J&J) validation, but the multiplexing ceiling caps the moat to targeted panels; NGS incumbents are well-funded and entrenched.
- economic_capture: 6/10 — captures ~70% GM + GAAP profitability with $458M net cash, but reimbursement risk (unprocessed payer claims, oncology MolDX not yet secured) and the oncology mix drag cap blended economics.
- time_to_monetize: 7/10 — MolDX coverage (~3–4 months), tumor-naive MRD launch (year-end), UNITY Confirm already ramping (>50% adoption) are concrete near-term monetization events.
Hypothesis verdict: STRENGTHENED — the QCT cost-advantage thesis is intact (revenue +64%, GAAP profitable, 70% GM, $548M cash, oncology +176%) and the 30% drawdown is substantially a true-up normalization + front-loaded commercial/R&D spend, not a broken moat. The disconfirming Q3 test is clean-qoq resumption + margin stabilization + MolDX timing.
Primary and supporting material
Sources
4 sources preserved from the latest qualified research update.